| n | % |
---|---|---|
Male: Female | 95:15 (6.3:1) | Â |
Age, mean (range) | 59 (28–89) |  |
Tumor sampling | ||
 Surgery | 16 | 14.5% |
 Biopsy | 94 | 85.5% |
Site | Â | Â |
 Base of tongue | 43 | 39.1% |
 Tonsil | 36 | 32.7% |
 Pharyngeal wall | 14 | 12.7% |
 Soft palate | 17 | 15.5% |
Squamous cell carcinoma type: | ||
 Non-keratinizing | 8 | 7.3% |
 Non-keratinizing with maturation | 18 | 16.4% |
 Keratinizing | 84 | 76.4% |
p16 status | Â | Â |
 p16-positive | 31 | 28.2% |
 p16-negative | 79 | 71.8% |
HPV status | ||
 HPV-positive | 16 | 14.5% |
 HPV-negative | 94 | 85.5% |
Risk-of-death categories | ||
 Low risk | 18 | 18.4% |
 Intermediate risk | 21 | 21.4% |
 High risk | 59 | 60.2% |
Treatment | ||
 RT + systemic | 63 | 57.3% |
 RT | 16 | 14.5% |
 Surgical + chemoradiotherapy | 9 | 8.2% |
 Palliative RT/CCRT | 4 | 3.6% |
 No data | 18 | 16.4% |
Follow-up status | ||
 Alive | 42 | 38.2% |
 Death | 68 | 61.8% |
Survival (months) | Â | Â |
 Mean | 23.1 |  |
 Median | 17 |  |
Median follow-up (months) | ||
 Alive group | 30.5 (14–90) |  |
 Died group | 10 (1–53) |  |